NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

NeoGenomics, Inc. (NEO) Stock Analysis

NeoGenomics, Inc. (NEO) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

NEO

$17.38

−$0.08 (−0.46%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NEO with… →

NEO Key Statistics

As of Sep 4, 2026
Trading
Open
$17.20
Previous Close
$17.46
Day's Range
16.87–17.47
52-Week Range
7.07–19.76
Volume
996.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.75
Valuation
Market Cap
$2.23B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
50.58
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.09
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.91
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.39
Financials (FY)
Revenue (FY)
$727.33M+10.11%
Net Income (FY)
−$108.03M
Profit marginThe share of revenue left as profit after all costs and taxes.
−6.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
128.48M
1-Year Return
+115.63%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
2.85M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NEO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+47.79%
2025−28.64%
2024+1.85%
2023+75.11%
2022−72.92%
2021−36.63%
2020+84.07%
2019+131.96%
2018+42.33%
2017+3.38%
2016 (partial year)+5.15%

As of September 4, 2026.

NEO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$727.33M−$108.03M−14.9%
2024$660.57M−$78.73M−11.9%
2023$591.64M−$87.97M−14.9%
2022$509.73M−$144.25M−28.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$727.33M$314.29M−$88.13M−$108.03M−14.9%
2024$660.57M$290.10M−$85.45M−$78.73M−11.9%
2023$591.64M$244.60M−$96.65M−$87.97M−14.9%
2022$509.73M$187.90M−$153.11M−$144.25M−28.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NEO Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricNEODiagnostics & Research medianvs median
P/S ratio2.914.9942% below
Profit margin−6.77%0.00%6.8 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NeoGenomics, Inc. (NEO) is capitalised at $2.23B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 2,500 employees.

NEO last closed at $17.38 on September 4, 2026. That is −$0.08 (−0.46%) against the previous close. The 52-week range on file runs from $7.07 to $19.76. The latest close sits 145.83% above that 52-week low.

Financial Health

In fiscal 2025, NeoGenomics, Inc. reported revenue of $727.33M. Against the prior fiscal year total of $660.57M, that is a change of +10.11%. The same year closed with a net loss of $108.03M. The reported profit margin is −6.77%. That is 6.8 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −0.39.

Across the 4 fiscal years on file, revenue moves from $509.73M in 2022 to $727.33M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 50.58. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.09. The price-to-sales ratio is 2.91. On price-to-sales that is 41.61% below the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +115.63%. Measured over 10 years, that is +8.07% a year compounded. Beta against the wider market is reported at 1.75. Daily returns over the trailing 10 years annualize to a volatility of 58.5%.

Growth & Income

No dividend is on file for NEO.

2026 is still running; the price is +47.79% year to date. The strongest complete calendar year on file is 2019 at +131.96%; the weakest is 2022 at −72.92%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

NeoGenomics, Inc. (NEO) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NeoGenomics, Inc. NEO $2.23B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. NeoGenomics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Visit website →